 [1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug METOPROLOL TARTRATE: METOPROLOL TARTRATE decreases the risk of myocardial infarction. This conclusion is based on a large, double-blind, placebo-controlled clinical study [0m
[34mmentioned in the METOPROLOL TARTRATE label, which showed that metoprolol reduced [0m[1;34m3[0m[34m-month mortality by [0m[1;34m36[0m[34m% in patients with suspected or definite myocardial infarction when treated as soon as possible [0m
[34mafter their arrival in the hospital. The beneficial effects were observed with both intravenous and oral administration of metoprolol.[0m
[1;34m2[0m[34m. Drug LABETALOL: Labetalol does not appear to directly increase or decrease the risk of myocardial infarction. However, there is a reported risk of myocardial infarction and ventricular dysrhythmias[0m
[34mfollowing abrupt discontinuation of labetalol in patients with coronary artery disease. This relationship is not clearly established and is based on reports of adverse reactions. The information is [0m
[34msourced from the LABETALOL label provided by FDAHandler.[0m
[1;34m3[0m[34m. Drug ATENOLOL: ATENOLOL decreases the risk of myocardial infarction. This is based on the information provided by FDAHandler, which states that ATENOLOL is indicated for the treatment of [0m
[34mhypertension and is used to lower blood pressure, thereby lowering the risk of fatal and non-fatal cardiovascular events, including myocardial infarctions. Additionally, ATENOLOL is used to reduce [0m
[34mcardiovascular mortality in hemodynamically stable patients with definite or suspected acute myocardial infarction. Clinical trials have demonstrated that ATENOLOL improves survival in patients with [0m
[34mmyocardial infarction and provides other clinical benefits such as reduced frequency of ventricular premature beats, reduced chest pain, and reduced enzyme elevation.[0m
[34m                ---------[0m
[34m                Does the beta blocker category of drugs increase the risk of[0m
[34m                myocardial infarction, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [31m Entity.AGENT [0m
*[1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the beta blocker category of drugs increase the risk of myocardial infarction, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Passage 1 indicates that METOPROLOL TARTRATE, a beta blocker, decreases the risk of myocardial infarction based on a large, double-blind, placebo-controlled clinical study."[0m[32m,[0m
[32m      [0m[32m"Passage 2 states that LABETALOL, another beta blocker, does not directly increase or decrease the risk of myocardial infarction, but there is a risk associated with abrupt discontinuation in [0m
[32mpatients with coronary artery disease."[0m[32m,[0m
[32m      [0m[32m"Passage 3 reports that ATENOLOL, also a beta blocker, decreases the risk of myocardial infarction, as supported by clinical trials and FDAHandler information."[0m[32m,[0m
[32m      [0m[32m"The evidence from passages 1 and 3 strongly suggests that beta blockers, as a category, decrease the risk of myocardial infarction. Passage 2 does not contradict this finding but rather [0m
[32mindicates a potential risk associated with discontinuation of the drug rather than its use."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The beta blocker category of drugs decreases the risk of myocardial infarction."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the beta blocker category of drugs increase the risk of myocardial infarction, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"Passage 1 indicates that METOPROLOL TARTRATE, a beta blocker, decreases the risk of myocardial infarction based on a large, double-blind, placebo-controlled clinical study."[0m[34m,[0m
[34m      [0m[34m"Passage 2 states that LABETALOL, another beta blocker, does not directly increase or decrease the risk of myocardial infarction, but there is a risk associated with abrupt discontinuation in [0m
[34mpatients with coronary artery disease."[0m[34m,[0m
[34m      [0m[34m"Passage 3 reports that ATENOLOL, also a beta blocker, decreases the risk of myocardial infarction, as supported by clinical trials and FDAHandler information."[0m[34m,[0m
[34m      [0m[34m"The evidence from passages 1 and 3 strongly suggests that beta blockers, as a category, decrease the risk of myocardial infarction. Passage 2 does not contradict this finding but rather [0m
[34mindicates a potential risk associated with discontinuation of the drug rather than its use."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The beta blocker category of drugs decreases the risk of myocardial infarction."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the beta blocker category of drugs increase the risk of myocardial infarction, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. Passage [0m[1;31m1[0m[31m indicates that METOPROLOL TARTRATE, a beta blocker, decreases the risk of myocardial infarction based on a large, double-blind, placebo-controlled clinical study.[0m
[1;31m2[0m[31m. Passage [0m[1;31m2[0m[31m states that LABETALOL, another beta blocker, does not directly increase or decrease the risk of myocardial infarction, but there is a risk associated with abrupt discontinuation in [0m
[31mpatients with coronary artery disease.[0m
[1;31m3[0m[31m. Passage [0m[1;31m3[0m[31m reports that ATENOLOL, also a beta blocker, decreases the risk of myocardial infarction, as supported by clinical trials and FDAHandler information.[0m
[1;31m4[0m[31m. The evidence from passages [0m[1;31m1[0m[31m and [0m[1;31m3[0m[31m strongly suggests that beta blockers, as a category, decrease the risk of myocardial infarction. Passage [0m[1;31m2[0m[31m does not contradict this finding but rather indicates a[0m
[31mpotential risk associated with discontinuation of the drug rather than its use.[0m
[31m        -----[0m
[31m        Final answer: The beta blocker category of drugs decreases the risk of myocardial infarction.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is generally sound, but it lacks precision in expressing the degree of certainty and the magnitude of change in risk. The evidence from METOPROLOL TARTRATE and [0m
[32mATENOLOL suggests a decrease in the risk of myocardial infarction, which is consistent with the known effects of beta blockers in reducing cardiac workload and improving survival after myocardial [0m
[32minfarction. However, the statement should specify that the conclusion is based on the evidence provided by the passages and that it reflects a general trend observed in the beta blocker category, [0m
[32mrather than an absolute rule applicable to all beta blockers. Additionally, the reasoning should acknowledge that the evidence is based on specific drugs within the category and may not necessarily [0m
[32mapply to all beta blockers. The final answer should reflect these nuances."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is generally sound, but it lacks precision in expressing the degree of certainty and the magnitude of change in risk. The evidence from METOPROLOL TARTRATE and [0m
[34mATENOLOL suggests a decrease in the risk of myocardial infarction, which is consistent with the known effects of beta blockers in reducing cardiac workload and improving survival after myocardial [0m
[34minfarction. However, the statement should specify that the conclusion is based on the evidence provided by the passages and that it reflects a general trend observed in the beta blocker category, [0m
[34mrather than an absolute rule applicable to all beta blockers. Additionally, the reasoning should acknowledge that the evidence is based on specific drugs within the category and may not necessarily [0m
[34mapply to all beta blockers. The final answer should reflect these nuances."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is generally sound, but it lacks precision in expressing the degree of certainty and the magnitude of change in risk. The evidence from METOPROLOL TARTRATE and[0m
[31mATENOLOL suggests a decrease in the risk of myocardial infarction, which is consistent with the known effects of beta blockers in reducing cardiac workload and improving survival after myocardial [0m
[31minfarction. However, the statement should specify that the conclusion is based on the evidence provided by the passages and that it reflects a general trend observed in the beta blocker category, [0m
[31mrather than an absolute rule applicable to all beta blockers. Additionally, the reasoning should acknowledge that the evidence is based on specific drugs within the category and may not necessarily [0m
[31mapply to all beta blockers. The final answer should reflect these nuances.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the beta blocker category of drugs increase the risk of myocardial infarction, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Passage 1 indicates that METOPROLOL TARTRATE, a beta blocker, decreases the risk of myocardial infarction based on a large, double-blind, placebo-controlled clinical study, suggesting strong [0m
[32mevidence for this specific drug."[0m[32m,[0m
[32m      [0m[32m"Passage 2 states that LABETALOL, another beta blocker, does not directly increase or decrease the risk of myocardial infarction, but there is a risk associated with abrupt discontinuation in [0m
[32mpatients with coronary artery disease. This indicates that the effect of LABETALOL on myocardial infarction risk is not clear, but the risk mentioned is related to discontinuation rather than the [0m
[32mdrug's therapeutic effect."[0m[32m,[0m
[32m      [0m[32m"Passage 3 reports that ATENOLOL, also a beta blocker, decreases the risk of myocardial infarction, as supported by clinical trials and FDAHandler information, providing strong evidence for this[0m
[32mspecific drug."[0m[32m,[0m
[32m      [0m[32m"Considering the evidence from METOPROLOL TARTRATE and ATENOLOL, there is strong evidence that at least some beta blockers decrease the risk of myocardial infarction. LABETALOL's passage does [0m
[32mnot provide evidence of an effect on myocardial infarction risk during its use."[0m[32m,[0m
[32m      [0m[32m"The conclusion is based on the evidence provided by the passages for specific drugs within the beta blocker category and reflects a general trend observed for these drugs. It is not an absolute[0m
[32mrule applicable to all beta blockers, and the degree of risk reduction may vary among different drugs in the category."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The beta blocker category of drugs generally decreases the risk of myocardial infarction, based on the evidence provided for specific drugs within the category."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the beta blocker category of drugs increase the risk of myocardial infarction, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"Passage 1 indicates that METOPROLOL TARTRATE, a beta blocker, decreases the risk of myocardial infarction based on a large, double-blind, placebo-controlled clinical study, suggesting strong [0m
[34mevidence for this specific drug."[0m[34m,[0m
[34m      [0m[34m"Passage 2 states that LABETALOL, another beta blocker, does not directly increase or decrease the risk of myocardial infarction, but there is a risk associated with abrupt discontinuation in [0m
[34mpatients with coronary artery disease. This indicates that the effect of LABETALOL on myocardial infarction risk is not clear, but the risk mentioned is related to discontinuation rather than the [0m
[34mdrug's therapeutic effect."[0m[34m,[0m
[34m      [0m[34m"Passage 3 reports that ATENOLOL, also a beta blocker, decreases the risk of myocardial infarction, as supported by clinical trials and FDAHandler information, providing strong evidence for this[0m
[34mspecific drug."[0m[34m,[0m
[34m      [0m[34m"Considering the evidence from METOPROLOL TARTRATE and ATENOLOL, there is strong evidence that at least some beta blockers decrease the risk of myocardial infarction. LABETALOL's passage does [0m
[34mnot provide evidence of an effect on myocardial infarction risk during its use."[0m[34m,[0m
[34m      [0m[34m"The conclusion is based on the evidence provided by the passages for specific drugs within the beta blocker category and reflects a general trend observed for these drugs. It is not an absolute[0m
[34mrule applicable to all beta blockers, and the degree of risk reduction may vary among different drugs in the category."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The beta blocker category of drugs generally decreases the risk of myocardial infarction, based on the evidence provided for specific drugs within the category."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the beta blocker category of drugs increase the risk of myocardial infarction, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. Passage [0m[1;31m1[0m[31m indicates that METOPROLOL TARTRATE, a beta blocker, decreases the risk of myocardial infarction based on a large, double-blind, placebo-controlled clinical study, suggesting [0m
[31mstrong evidence for this specific drug.[0m
[1;31m2[0m[31m. Passage [0m[1;31m2[0m[31m states that LABETALOL, another beta blocker, does not directly increase or decrease the risk of myocardial infarction, but there is a risk associated with abrupt discontinuation in [0m
[31mpatients with coronary artery disease. This indicates that the effect of LABETALOL on myocardial infarction risk is not clear, but the risk mentioned is related to discontinuation rather than the [0m
[31mdrug's therapeutic effect.[0m
[1;31m3[0m[31m. Passage [0m[1;31m3[0m[31m reports that ATENOLOL, also a beta blocker, decreases the risk of myocardial infarction, as supported by clinical trials and FDAHandler information, providing strong evidence for this [0m
[31mspecific drug.[0m
[1;31m4[0m[31m. Considering the evidence from METOPROLOL TARTRATE and ATENOLOL, there is strong evidence that at least some beta blockers decrease the risk of myocardial infarction. LABETALOL's passage does not [0m
[31mprovide evidence of an effect on myocardial infarction risk during its use.[0m
[1;31m5[0m[31m. The conclusion is based on the evidence provided by the passages for specific drugs within the beta blocker category and reflects a general trend observed for these drugs. It is not an absolute [0m
[31mrule applicable to all beta blockers, and the degree of risk reduction may vary among different drugs in the category.[0m
[31m        -----[0m
[31m        Final answer: The beta blocker category of drugs generally decreases the risk of myocardial infarction, based on the evidence provided for specific drugs within the category.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The revised reasoning is more precise and acknowledges the nuances of the evidence provided. It correctly distinguishes between the effects of specific beta blockers and the potential[0m
[32mvariability within the drug category. The final answer appropriately reflects the general trend observed in the beta blocker category based on the evidence from METOPROLOL TARTRATE and ATENOLOL, while[0m
[32malso considering the lack of clear effect from LABETALOL during its use. The reasoning does not overgeneralize the findings and maintains an appropriate degree of certainty based on the available [0m
[32mevidence. No further critique is necessary."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The revised reasoning is more precise and acknowledges the nuances of the evidence provided. It correctly distinguishes between the effects of specific beta blockers and the potential[0m
[34mvariability within the drug category. The final answer appropriately reflects the general trend observed in the beta blocker category based on the evidence from METOPROLOL TARTRATE and ATENOLOL, while[0m
[34malso considering the lack of clear effect from LABETALOL during its use. The reasoning does not overgeneralize the findings and maintains an appropriate degree of certainty based on the available [0m
[34mevidence. No further critique is necessary."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The revised reasoning is more precise and acknowledges the nuances of the evidence provided. It correctly distinguishes between the effects of specific beta blockers and the [0m
[31mpotential variability within the drug category. The final answer appropriately reflects the general trend observed in the beta blocker category based on the evidence from METOPROLOL TARTRATE and [0m
[31mATENOLOL, while also considering the lack of clear effect from LABETALOL during its use. The reasoning does not overgeneralize the findings and maintains an appropriate degree of certainty based on [0m
[31mthe available evidence. No further critique is necessary.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mcategory_effect_tool[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"category_effect_tool"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"label"[0m[32m: [0m[32m"decrease"[0m[32m,[0m
[32m    [0m[32m"confidence"[0m[32m: [0m[1;32m0.9[0m[32m,[0m
[32m    [0m[32m"probability"[0m[32m: [0m[1;32m0.8[0m[32m,[0m
[32m    [0m[32m"frequency"[0m[32m: [0m[32m"common"[0m[32m,[0m
[32m    [0m[32m"evidence"[0m[32m: [0m[32m"strong"[0m[32m,[0m
[32m    [0m[32m"justification"[0m[32m: [0m[32m"Based on the passages provided, METOPROLOL TARTRATE and ATENOLOL, both beta blockers, have been shown to decrease the risk of myocardial infarction, with strong evidence from [0m
[32mclinical trials and FDAHandler information. LABETALOL does not have a clear effect on myocardial infarction risk during its therapeutic use, but the risk mentioned is associated with discontinuation. [0m
[32mThe general trend observed from the evidence is that beta blockers decrease the risk of myocardial infarction, although the degree of risk reduction may vary among different drugs in the category."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-myocardial infarction-beta blocker[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mcategory_effect_tool[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m
